Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9273492 | Seminarios de la Fundación Española de Reumatología | 2005 | 11 Pages |
Abstract
Rheumatoid arthritis (RA) is a severe disease that leads to joint destruction, loss of function and premature death. To achieve the induction of remission is a major therapeutic goal. The use of conventional disease-modifying anti-rheumatic drugs (DMARDs) as monotherapy rarely allows to achieve and maintain an adecuate clinical response over the course of the disease. This article reviews the role of the combination therapy with conventional DMARDs in the early-onset and refractory rheumatoid disease. In addition, the role that should play these combination therapies in the current therapeutic armamentarium of RA after the advent of the new biologic agents is critically discussed.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Immunology, Allergology and Rheumatology
Authors
José Luis Andreu-Sánchez, Jesús Sanz-Sanz, Pilar Muñoz-Carreño, LucÃa Silva-Fernández,